{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:05:13Z","timestamp":1791360313429,"version":"4.3.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1038\/sj.gt.3302624","type":"journal-article","created":{"date-parts":[[2005,10,18]],"date-time":"2005-10-18T11:30:21Z","timestamp":1129635021000},"page":"S103-S110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["Downstream processing of viral vectors and vaccines"],"prefix":"10.1038","volume":"12","author":[{"given":"R","family":"Morenweiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,10,18]]},"reference":[{"key":"BF3302624_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.270.5235.475","volume":"270","author":"R Blaese","year":"1995","unstructured":"Blaese R et al. T lymphocyte-directed gene therapy for ADA deficiency SCID: initial trial results after 4 years. Science 1995; 270: 475\u2013480.","journal-title":"Science"},{"key":"BF3302624_CR2","unstructured":"The Journal of Gene Medicine, Gene Therapy Clinical Trials, Charts and Tables, Vectors, 2005; http:\/\/82.182.180.141\/trials\/FMPro?-db=Trials.FP5&-format=vectors.html&-lay=Vectors&-findAll."},{"key":"BF3302624_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0958-1669(98)80112-2","volume":"9","author":"A Lyddiatt","year":"1998","unstructured":"Lyddiatt A, O'Sullivan D . Biochemical recovery and purification of gene therapy vectors. Curr Opin Biotechnol 1998; 9: 177\u2013185.","journal-title":"Curr Opin Biotechnol"},{"key":"BF3302624_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0958-1669(00)00080-X","volume":"11","author":"N Wu","year":"2000","unstructured":"Wu N, Ataai M . Production of viral vectors for gene therapy applications. Curr Opin Biotechnol 2000; 11: 205\u2013208.","journal-title":"Curr Opin Biotechnol"},{"key":"BF3302624_CR5","first-page":"211","volume":"6","author":"G Braas","year":"1996","unstructured":"Braas G, Searle P, Slater N, Lyddiatt A . Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 1996; 6: 211\u2013228.","journal-title":"Bioseparation"},{"key":"BF3302624_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0167-7799(00)01475-X","volume":"18","author":"N Guilherme","year":"2000","unstructured":"Guilherme N, Monteiro G, Prozeres D, Cabral J . Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. TIBTECH 2000; 18: 380\u2013388.","journal-title":"TIBTECH"},{"key":"BF3302624_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973\u2013985.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0166-0934(94)90005-1","volume":"46","author":"K Saha","year":"1994","unstructured":"Saha K, Lin Y-C, Wong P . A single method for obtaining highly viable virus from culture supernatant. J Virol Methods 1994; 46: 349\u2013352.","journal-title":"J Virol Methods"},{"key":"BF3302624_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/BF01314870","volume":"71","author":"M Aboud","year":"1982","unstructured":"Aboud M, Wolfson M, Hassan Y, Huleihel M . Rapid purification of extracellular and intracellular Moloney murine leukemia virus. Arch Virol 1982; 71: 185\u2013195.","journal-title":"Arch Virol"},{"key":"BF3302624_CR10","first-page":"504","volume":"2","author":"F Morling","year":"1995","unstructured":"Morling F, Russell S . Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Therapy 1995; 2: 504\u2013508.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/bp980106m","volume":"15","author":"S Andreadis","year":"1999","unstructured":"Andreadis S et al. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 1999; 15: 1\u201311.","journal-title":"Biotechnol Prog"},{"key":"BF3302624_CR12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1089\/aid.1990.6.1379","volume":"6","author":"L Hammar","year":"1990","unstructured":"Hammar L, Gilljam G . Extraction of HIV-1 in aqueous two-phase systems to obtain a high yield of gp120. AIDS Res Hum Retroviruses 1990; 6: 1379\u20131388.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"BF3302624_CR13","first-page":"20","volume":"37","author":"R Morenweiser","year":"2004","unstructured":"Morenweiser R . Amersham Biosciences. Downstream 2004; 37: 20\u201321.","journal-title":"Downstream"},{"key":"BF3302624_CR14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/jvi.25.3.923-927.1978","volume":"25","author":"M McGrath","year":"1978","unstructured":"McGrath M, Witte O, Pincus T, Weissman I . Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J Virol 1978; 25: 923\u2013927.","journal-title":"J Virol"},{"key":"BF3302624_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0021-9673(99)00386-6","volume":"844","author":"A Ljunglof","year":"1999","unstructured":"Ljunglof A, Bergvall P, Bhikhabhai R, Hjorth R . Direct visualization of plasmid DNA in individual chromatography adsorbent particles by confocal scanning laser microscopy. J Chromatogr A 1999; 844: 129\u2013135.","journal-title":"J Chromatogr A"},{"key":"BF3302624_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/JVI.76.2.552-559.2002","volume":"76","author":"M Martin","year":"2002","unstructured":"Martin M, El Azher M, Vasseur M . Ionic strength- and temperature-induced KCa shifts in the uncoating reaction of rotavirus strains RF and SA11: correlation with membrane permeabilization. J Virol 2002; 76: 552\u2013559.","journal-title":"J Virol"},{"key":"BF3302624_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/bit.20270","volume":"88","author":"R Specht","year":"2004","unstructured":"Specht R et al. Densonucleosis virus purification by ion exchange membranes. Biotechnol Bioeng 2004; 88: 465\u2013473.","journal-title":"Biotechnol Bioeng"},{"key":"BF3302624_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1089\/hum.1995.6.11-1403","volume":"6","author":"B Huyghe","year":"1995","unstructured":"Huyghe B et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995; 6: 1403\u20131416.","journal-title":"Hum Gene Ther"},{"key":"BF3302624_CR19","first-page":"16","volume":"13","author":"S Herzer","year":"2003","unstructured":"Herzer S, Wegmann T, Beckett P . Isoelectric titration curves of viral particles as an evaluation tool for ion exchange chromatography. Life Sci News 2003; 13: 16\u201318.","journal-title":"Life Sci News"},{"key":"BF3302624_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bbrc.2003.08.149","volume":"310","author":"R Valdes","year":"2003","unstructured":"Valdes R et al. Hepatitis B surface antigen immunopurification using a plant-derived specific antibody produced in large scale. Biochim Biophys Res Commun 2003; 310: 742\u2013747.","journal-title":"Biochim Biophys Res Commun"},{"key":"BF3302624_CR21","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1089\/hum.1998.9.18-2745","volume":"9","author":"D Grimm","year":"1998","unstructured":"Grimm D, Kern A, Rittner K, Kleinschmidt J . Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745\u20132760.","journal-title":"Hum Gene Ther"},{"key":"BF3302624_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/00003495-200060020-00002","volume":"60","author":"W Walther","year":"2000","unstructured":"Walther W, Stein U . Viral vectors for gene transfer. Drugs 2000; 60: 249\u2013271.","journal-title":"Drugs"},{"key":"BF3302624_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1006\/viro.2000.0743","volume":"280","author":"F Higashikawa","year":"2001","unstructured":"Higashikawa F, Chang L . Kinetic analyses of stability of simple and complex retroviral vectors. Virology 2001; 280: 124\u2013133.","journal-title":"Virology"},{"key":"BF3302624_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/sj.gt.3301201","volume":"7","author":"D Darling","year":"2000","unstructured":"Darling D et al. Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titer. Gene Therapy 2000; 7: 914\u2013923.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/bit.10388","volume":"80","author":"M Kuiper","year":"2002","unstructured":"Kuiper M, Sanches R, Walford J, Slater N . Purification of a functional gene therapy vector derived from Moloney murine leukemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol Bioeng 2002; 80: 445\u2013453.","journal-title":"Biotechnol Bioeng"},{"key":"BF3302624_CR26","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/sj.gt.3302094","volume":"10","author":"V Baekelandt","year":"2003","unstructured":"Baekelandt V et al. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Therapy 2003; 10: 1933\u20131940.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR27","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/sj.gt.3301587","volume":"8","author":"B Zhang","year":"2001","unstructured":"Zhang B et al. A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Therapy 2001; 8: 1745\u20131751.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/sj.gt.3301188","volume":"7","author":"J Reiser","year":"2000","unstructured":"Reiser J . Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Therapy 2000; 7: 910\u2013913.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0264-410X(97)00196-5","volume":"16","author":"S Richieri","year":"1998","unstructured":"Richieri S et al. Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine 1998; 16: 119\u2013129.","journal-title":"Vaccine"},{"key":"BF3302624_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.jim.2900529","volume":"20","author":"L Bondoc","year":"1998","unstructured":"Bondoc L, Fitzpatrick S . Size distribution analysis of recombinant adenovirus using disc centrifugation. J Ind Microbiol Biotechnol 1998; 20: 317\u2013322.","journal-title":"J Ind Microbiol Biotechnol"},{"key":"BF3302624_CR31","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1089\/10430340260355338","volume":"3","author":"A Green","year":"2002","unstructured":"Green A et al. A new scalable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 2002; 3: 1921\u20131934.","journal-title":"Hum Gene Ther"},{"key":"BF3302624_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jgm.503","volume":"6","author":"A Kamen","year":"2004","unstructured":"Kamen A, Henry O . Development and optimization of an adenovirus production process. J Gene Med 2004; 6: 184\u2013192.","journal-title":"J Gene Med"},{"key":"BF3302624_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1146\/annurev.mi.49.100195.004111","volume":"49","author":"A Smith","year":"1995","unstructured":"Smith A . Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49: 807\u2013838.","journal-title":"Annu Rev Microbiol"},{"key":"BF3302624_CR34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/sj.gt.3301190","volume":"7","author":"F Blanche","year":"2000","unstructured":"Blanche F et al. An improved anion-exchange HPLC method for the detection and purification of adenoviral particles. Gene Therapy 2000; 7: 1055\u20131062.","journal-title":"Gene Therapy"},{"key":"BF3302624_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jviromet.2003.09.002","volume":"114","author":"R Smith","year":"2003","unstructured":"Smith R, Ding C, Kotin R . Serum-free production and column purification of adeno-associated virus type 5. J Virol Meth 2003; 114: 115\u2013124.","journal-title":"J Virol Meth"},{"key":"BF3302624_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jviromet.2004.07.001","volume":"121","author":"A Davidoff","year":"2004","unstructured":"Davidoff A et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 2004; 121: 209\u2013215.","journal-title":"J Virol Methods"},{"key":"BF3302624_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/1521-2254(200011\/12)2:6<444::AID-JGM132>3.0.CO;2-1","volume":"2","author":"C O'Riordan","year":"2000","unstructured":"O'Riordan C, Lachapelle A, Vincent K, Wadsworth S . Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). Gene Med 2000; 2: 444\u2013454.","journal-title":"Gene Med"},{"key":"BF3302624_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/8470","volume":"5","author":"C Summerford","year":"1999","unstructured":"Summerford C, Samulski R . Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med 1999; 5: 587\u2013588.","journal-title":"Nat Med"},{"key":"BF3302624_CR39","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","volume":"72","author":"C Summerford","year":"1998","unstructured":"Summerford C, Samulski R . Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 vectors. J Virol 1998; 72: 1438\u20131445.","journal-title":"J Virol"},{"key":"BF3302624_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1006\/mthe.2001.0462","volume":"4","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, O'Connor E, Hildinger M, Wilson J . A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther 2001; 4: 372\u2013374.","journal-title":"Mol Ther"},{"key":"BF3302624_CR41","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/10430349950018427","volume":"10","author":"K Clark","year":"1999","unstructured":"Clark K, Liu M, McGrath J, Johnson P . Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses. Hum Gene Ther 1999; 10: 1031\u20131039.","journal-title":"Hum Gene Ther"},{"key":"BF3302624_CR42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1525-0016(02)90719-7","volume":"6","author":"N Brument","year":"2002","unstructured":"Brument N et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther 2002; 6: 678\u2013686.","journal-title":"Mol Ther"},{"key":"BF3302624_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jgm.505","volume":"6","author":"V Blouin","year":"2004","unstructured":"Blouin V et al. Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med 2004; 6: 223\u2013228.","journal-title":"J Gene Med"},{"key":"BF3302624_CR44","unstructured":"Siegel J . Gene Therapy: Is There Oversight for Patient Safety?. Testimony before the Senate Committee on Health, Education, Labor and Pensions, Subcommittee on Public Health, February 2, 2000."},{"key":"BF3302624_CR45","unstructured":"The European Agency for the Evaluation of Medicinal Products, Note for Guidance on Quality, Preclinical and clinical aspects of gene transfer medicinal products, 9CPMP\/BWP\/3088\/99, London, April 24, 2001, pp 1\u201333, http:\/\/www.emea.eu.int\/pdfs\/human\/bwp\/308899en.pdf."},{"key":"BF3302624_CR46","unstructured":"Food and Drug Administration [Docket No. 2004D\u20130465], Draft Guidance for Food and Drug Administration Review Staff and Sponsors: Content and Review of Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications, November 1, 2004, pp 1\u20134, http:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/cb0240.pdf."},{"key":"BF3302624_CR47","unstructured":"Food and Drug Administration Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy, dated March 1998, http:\/\/www.fda.gov\/cber\/gdlns\/somgene.pdf."},{"key":"BF3302624_CR48","unstructured":"Food and Drug Administration Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products, dated November 1995, http:\/\/www.fda.gov\/cder\/guidance\/phase1.pdf."},{"key":"BF3302624_CR49","unstructured":"Food and Drug Administration Draft Guidance for Reviewers: Instructions and Template for Chemistry, Manufacturing, and Control (CMC) Reviewers of Human Somatic Cell Therapy Investigational New Drug Applications (INDs), dated August 2003, http:\/\/www.fda.gov\/cber\/gdlns\/cmcsomcell.pdf."},{"key":"BF3302624_CR50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/0470842385.ch18","volume-title":"Gene Therapy Technologies, Applications and Regulations","author":"F Borellini","year":"1999","unstructured":"Borellini F, Ostrove J . The transfer of technology from the laboratory to the clinic: in-process controls and final product testing. In: Meager A (ed). Gene Therapy Technologies, Applications and Regulations. John Wiley & Sons Ltd: New York, 1999, pp 359\u2013373."},{"key":"BF3302624_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1073\/pnas.0409141102","volume":"102","author":"Z-Z Su","year":"2005","unstructured":"Su Z-Z et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci USA 2005; 102: 1059\u20131064.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/3302624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302624","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:33:45Z","timestamp":1684863225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/3302624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":51,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["BF3302624"],"URL":"https:\/\/doi.org\/10.1038\/sj.gt.3302624","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]},"assertion":[{"value":"18 October 2005","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}